NKG2D CARs as cell therapy for cancer

Cancer Journal (United States)

Volumn 20, Issue 2, 2014, Pages 156-159

  Sentman, Charles L ^a   Meehan, Kenneth R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

adoptive cell therapy; Chimeric antigen receptor; cytokines; immunosuppression; immunotherapy; NK cells; T cells; toxicity

Indexed keywords

BORTEZOMIB; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 9; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

CANCER GROWTH; CANCER THERAPY; CELL EXPANSION; CELL THERAPY; CROSS REACTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; IMMUNOCOMPETENT CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULARLY TARGETED THERAPY; NEOPLASMS; T LYMPHOCYTE;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84897502067     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000029     Document Type: Review

References (48)

1. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388-398.
2. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007;117:1204-1212.
3. Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
4. Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 2002;17:19-29.
5. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781-790.
6. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
7. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005;106:1544-1551.
8. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 2006;66:5927-5933.
9. Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 2007;67:11029-11036.
10. Barber A, Zhang T, DeMars LR, et al. Chimeric NKG2D receptorbearing T cells as immunotherapy for ovarian cancer. Cancer Res. 2007;67:5003-5008.
11. Barber A, Zhang T, Megli CJ, et al. Chimeric NKG2D receptorexpressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008;36:1318-1328.
12. Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011;18:509-516.
13. Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009;183:6939-6947.
14. Barber A, Sentman CL. Chimeric NKG2D T cells require both T celland host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol. 2009;183:2365-2372.
15. Spear P, Barber A, Rynda-Apple A, et al. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. J Immunol. 2012;188:6389-6398.
16. Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR) and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2013;2:e23564.
17. Zhang T, Sentman CL. Cancer immunotherapy using a bi-specific NK receptor-fusion protein that engages both T cells and tumor cells. Cancer Res. 2011;71:2066-2076.
18. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol. 2013;190:2455-2463.
19. Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777-1786.
20. Lehner M, Gotz G, Proff J, et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One. 2012;7:e31210.
21. Song DG, Ye Q, Santoro S, et al. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013;24:295-305.
22. Barber A, Sentman CL. NKG2D receptor regulates human effector T-cell cytokine production. Blood. 2011;117:6571-6581.
23. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
24. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
25. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
26. Song H, Hur DY, Kim K-E, et al. IL-2/IL-18 prevent the downmodulation of NKG2D by TGF-β in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol. 2006;242:39-45.
27. Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240-249.
28. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-738.
29. Groh V, Bruhl A, El-Gabalawy H, et al. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003;100:9452-9457.
30. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186-1190.
31. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases. Int J Cancer. 2006;118:684-687.
32. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105:251-258.
33. Meehan KR, Talebian L, Tosteson TD, et al. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant. 2013;19:129-137.
34. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-3057.
35. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009;37:956-968.
36. Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010;37:1191-1197.
37. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
38. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36:133-151.
39. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-851.
40. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863-871.
41. Sentman CL. Challenges of creating effective chimeric antigen receptors for cancer therapy. Immunotherapy. 2013;5:783-785.
42. ParkhurstMR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17:6287-6297.
43. Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-252.
44. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005;5:363-374.
45. Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012;122:3718-3730.
46. Skov S. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136-11145.
47. Vales-Gomez M, Chisholm SE, Cassady-Cain RL, et al. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008;68:1546-1554.
48. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321-6329.